Alaunos Therapeutics Inc (TCRT)
2.009
-0.03
(-1.50%)
USD |
NASDAQ |
Nov 04, 16:00
2.13
+0.12
(+6.01%)
Pre-Market: 08:53
Alaunos Therapeutics Cash from Financing (Quarterly): 0.00 for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | -11.98M |
| March 31, 2023 | -6.158M |
| December 31, 2022 | 8.474M |
| September 30, 2022 | -2.107M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | -0.186M |
| September 30, 2021 | 24.93M |
| June 30, 2021 | 0.019M |
| March 31, 2021 | 1.017M |
| December 31, 2020 | 0.40M |
| September 30, 2020 | 0.027M |
| June 30, 2020 | 0.012M |
| March 31, 2020 | 101.68M |
| December 31, 2019 | 3.03M |
| September 30, 2019 | 55.89M |
| June 30, 2019 | 0.23M |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 41.35M |
| September 30, 2018 | 0.00 |
| June 30, 2018 | -0.304M |
| Date | Value |
|---|---|
| March 31, 2018 | -0.731M |
| December 31, 2017 | -1.028M |
| September 30, 2017 | 0.001M |
| June 30, 2017 | 46.30M |
| March 31, 2017 | 0.029M |
| December 31, 2016 | -0.484M |
| September 30, 2016 | 0.00 |
| June 30, 2016 | -0.669M |
| March 31, 2016 | 0.365M |
| December 31, 2015 | 1.063M |
| September 30, 2015 | 0.093M |
| June 30, 2015 | 0.565M |
| March 31, 2015 | 96.62M |
| December 31, 2014 | 6.551M |
| September 30, 2014 | 3.706M |
| June 30, 2014 | 0.348M |
| March 31, 2014 | 0.837M |
| December 31, 2013 | 53.63M |
| September 30, 2013 | 0.202M |
| June 30, 2013 | -0.001M |
| March 31, 2013 | 0.706M |
| December 31, 2012 | -0.45M |
| September 30, 2012 | 0.024M |
| June 30, 2012 | 0.101M |
| March 31, 2012 | 49.31M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-11.98M
Minimum
Jun 2023
101.68M
Maximum
Mar 2020
6.271M
Average
--
Median
Mar 2022
Cash from Financing (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 122.08M |
| Oragenics Inc | 0.8212M |
| Cocrystal Pharma Inc | 0.00 |
| Cara Therapeutics Inc | -0.61M |
| Jaguar Health Inc | 12.57M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.681M |
| Free Cash Flow | -17.36M |
| Free Cash Flow Per Share (Quarterly) | -1.050 |
| Free Cash Flow to Equity (Quarterly) | -1.681M |
| Free Cash Flow Yield | -539.6% |